Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter Pylori infection

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Syrios, John ^a   Sougioultzis, Stavros ^a   Xynos, Ioannis D ^a   Kavantzas, Nikolaos ^a   Kosmas, Christos ^b   Agrogiannis, George ^a   Griniatsos, John ^a   Karavokyros, Ioannis ^a   Pikoulis, Emmanouil ^a   Patsouris, Efstratios S ^a   Tsavaris, Nikolas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA; IMMUNOGLOBULIN G;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CYTOMETRY; FEMALE; GASTRECTOMY; HAZARD RATIO; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PLOIDY; PROGNOSIS; RETROSPECTIVE STUDY; SEROLOGY; STOMACH CANCER;

ADENOCARCINOMA; AGED; HELICOBACTER INFECTIONS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84862486326     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-264     Document Type: Article

References (36)

1. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004, 240(5):808-816. 10.1097/01.sla.0000143245.28656.15, 1356486, 15492562.
2. Fujitani K, Yang HK, Kurokawa Y, do Park J, Tsujinaka T, Park BJ, Fukuda H, Noh SH, Boku N, Bang YJ, et al. Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol 2008, 38(7):504-506. 10.1093/jjco/hyn058, 18617536.
3. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009, 374(9688):477-490. 10.1016/S0140-6736(09)60617-6, 19625077.
4. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008, 61(2):301-307.
5. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007, 18(5):886-891. 10.1093/annonc/mdl501, 17298958.
6. Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos G, Felekouras E, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol 2011, 37(4):312-318. 10.1016/j.ejso.2011.01.019, 21300519.
7. Lin SZ, Tong HF, You T, Yu YJ, Wu WJ, Chen C, Zhang W, Ye B, Li CM, Zhen ZQ, et al. Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol 2008, 134(2):187-192.
8. Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?. World J Surg 2006, 30(1):21-27. 10.1007/s00268-005-0129-3, 16369718.
9. Tsavaris N, Kavantzas N, Tsigritis K, Xynos ID, Papadoniou N, Lazaris A, Kosmas C, Agrogiannis G, Dokou A, Felekouras E, et al. Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. BMC Cancer 2009, 9:264. 10.1186/1471-2407-9-264, 2734865, 19646258.
10. Chelidonis G, Kavantzas N, Patsouris E, Pagaki E, Athanasiadou AM, Agrogiannis G, Athanasiadou P. DNA ploidy, E-cadherin, beta-catenin expression and their clinicopathologic significance in imprints of non-small cell lung cancer. Anal Quant Cytol Histol 2009, 31(5):332-339.
11. Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F, Papadoniou N, Tzivras M, Balatsos V, Koufos C, et al. Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol 2005, 11(45):7174-7178.
12. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20. 10.1056/NEJMoa055531, 16822992.
13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730. 10.1056/NEJMoa010187, 11547741.
14. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004, 22(12):2395-2403. 10.1200/JCO.2004.08.154, 15197201.
15. Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010, 21(9):1779-1785. 10.1093/annonc/mdq032, 20150573.
16. Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol 2010, 66(4):797-805. 10.1007/s00280-010-1295-z, 20221831.
17. Jeung HC, Rha SY, Jang WI, Noh SH, Chung HC. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg 2002, 89(4):460-466. 10.1046/j.0007-1323.2001.02048.x, 11952588.
18. Wang S, Sun Z, Wang S. Study on factors influencing survival in patients with advanced gastric carcinoma after resection by Cox's proportional hazard model. Zhonghua Zhong Liu Za Zhi 1996, 18(6):433-435.
19. Belien JA, Buffart TE, Gill AJ, Broeckaert MA, Quirke P, Meijer GA, Grabsch HI. Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival. Br J Cancer 2009, 101(6):1011-1018. 10.1038/sj.bjc.6605266, 2743350, 19738619.
20. Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer M, Reith A, Spieler P, Bocking A. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001, 23(2):89-95.
21. Ormerod MG, Tribukait B, Giaretti W. Consensus report of the task force on standardisation of DNA flow cytometry in clinical pathology. DNA Flow Cytometry Task Force of the European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998, 17(2):103-110.
22. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010, 10(6):403-414. 10.1038/nrc2857, 2957472, 20495574.
23. Baba H, Korenaga D, Okamura T, Saito A, Watanabe A, Sugimachi K. Prognostic significance of DNA content with special reference to age in gastric cancer. Cancer 1989, 63(9):1768-1772.
24. Danova M, Riccardi A, Mazzini G, Wilson G, Dionigi P, Brugnatelli S, Fiocca R, Ucci G, Jemos V, Ascari E. Flow cytometric analysis of paraffin-embedded material in human gastric cancer. Anal Quant Cytol Histol 1988, 10(3):200-206.
25. Osterheld MC, Caron L, Demierre M, Laurini R, Bosman FT. DNA-ploidy in advanced gastric carcinoma is less heterogeneous than in early gastric cancer. Cell Oncol 2004, 26(1-2):21-29.
26. Fujimaki E, Sasaki K, Nakano O, Chiba S, Tazawa H, Yamashiki H, Orii S, Sugai T. DNA ploidy heterogeneity in early and advanced gastric cancers. Cytometry 1996, 26(2):131-136. 10.1002/(SICI)1097-0320(19960615)26:2<131::AID-CYTO6>3.0.CO;2-J, 8817089.
27. Helicobacter and Cancer Collaborative Group Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49(3):347-353. 10.1136/gut.49.3.347, 1728434, 11511555, Helicobacter and Cancer Collaborative Group.
28. Correa P, Piazuelo MB. Helicobacter pylori Infection and Gastric Adenocarcinoma. US Gastroenterol Hepatol Rev 2011, 7(1):59-64. 3158605, 21857882.
29. Gonzalez CA, Megraud F, Buissonniere A, Lujan Barroso L, Agudo A, Duell EJ, Boutron-Ruault MC, Clavel-Chapelon F, Palli D, Krogh V, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol 2012, 23(5):1320-1324. 10.1093/annonc/mdr384, 21917738.
30. Mitchell H, English DR, Elliott F, Gengos M, Barrett JH, Giles GG, Forman D. Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Aliment Pharmacol Ther 2008, 28(7):903-910.
31. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, Stolte M, Jauch KW, Hatz RA. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol 2006, 7(3):211-222. 10.1016/S1470-2045(06)70586-1, 16510330.
32. Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, Vindigni C, Santucci A, Figura N, Roviello F. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer 2009, 115(10):2071-2080. 10.1002/cncr.24253, 19280589.
33. Kang SY, Han JH, Ahn MS, Lee HW, Jeong SH, Park JS, Cho YK, Han SU, Kim YB, Kim JH, et al. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer 2012, 130(4):948-958. 10.1002/ijc.26081, 21425257.
34. Apostolopoulos P, Vafiadis-Zouboulis I, Tzivras M, Kourtessas D, Katsilambros N, Archimandritis A. Helicobacter pylori (H pylori) infection in Greece: the changing prevalence during a ten-year period and its antigenic profile. BMC Gastroenterol 2002, 2:11. 10.1186/1471-230X-2-11, 115842, 12014991.
35. Hobsley M, Tovey FI, Holton J. Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology 2007, 132(5):2076.
36. Qiu HB, Zhang LY, Keshari RP, Wang GQ, Zhou ZW, Xu DZ, Wang W, Zhan YQ, Li W. Relationship between H. Pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer 2010, 10:374. 10.1186/1471-2407-10-374, 2914705, 20637122.